A 4 Month Extension to a 12 Month, Randomized, Open-label, Multicenter, Study to Assess the Long-term Safety of Aliskiren 150 mg Alone and 300 mg Alone or With the Optional Addition of Hydrochlorothiazide (12.5 mg or 25 mg) in Patients With Essential Hypertension.
Latest Information Update: 04 Mar 2011
Price :
$35 *
At a glance
- Drugs Aliskiren (Primary) ; Hydrochlorothiazide
- Indications Essential hypertension
- Focus Adverse reactions
- 24 Feb 2011 Actual end date (Feb 2006) added as reported by ClinicalTrials.gov.
- 24 Feb 2011 Additional locations added as reported by ClinicalTrials.gov.
- 14 Jan 2008 Status changed from in progress to completed.